February 2010 Clinical Laboratory News: Industry Profiles

CLN Banner Logo

February 2010: Volume 36, Number 2

QIAGEN Completes Purchase of SABiosciences

QIAGEN announced the completion of its acquisition of SABiosciences, a developer and manufacturer of PCR assay panels. The closing follows approval by SABiosciences’ stockholders and the expiration of the statutory 30-day waiting period as required by law. The acquisition gives QIAGEN access to more than 100 PCR assay panels for the analysis of DNA, RNA, and microRNA targets associated with specific diseases or pathways. “I would like to use this opportunity to welcome our new employees to QIAGEN,” said Peer M. Schatz, chief executive officer of QIAGEN. “Their competence will help us leverage the combined company’s value proposition in the field of biomarker discovery and validation for the development of future diagnostics and pharmaceuticals.” QIAGEN plans to further expand the business of the disease- and pathway-focused assay panels, as well as develop SABiosciences’ headquarters in Frederick, Md. as a center of excellence in biological content development. The acquisition was valued at approximately $90 million in cash.

Abbott to Pay $123 Million for STARLIMS

Abbott announced a definitive agreement to acquire STARLIMS Technologies, a provider of laboratory information management systems, for approximately $123 million in cash. The acquisition is expected to strengthen Abbott’s standing in the global diagnostics market by providing web-based applications to help labs more efficiently store, retrieve, and analyze clinical data. “The acquisition of STARLIMS will provide Abbott with leading products to build upon existing technologies and expertise in the emerging field of healthcare informatics,” said Edward L. Michael, executive vice president of diagnostic products at Abbott. “STARLIMS’ advanced web-based technologies can help our customers operate efficiently across the core laboratory, molecular, and point-of-care segments of the global diagnostics market.” Abbott expects the transaction to close in the first quarter of 2010 following customary closing procedures.

Clarient Buys Applied Genomics for $17.6 Million

Clarient announced that it has acquired Applied Genomics (AGI) in an all-stock merger valued at approximately $17.6 million. As a result of this acquisition, AGI has become a wholly-owned subsidiary of Clarient. “AGI and Clarient represent a strong and technical fit providing for multiple proprietary tests that can be commercialized via the Clarient national footprint,” said Ron Andrews, chief executive officer of Clarient. “The combination of these organizations populates the Clarient proprietary pipeline of cancer tests, including the planned commercial launch of an important lung cancer test, Pulmotype, in the first quarter of 2010, followed by a series of proprietary tests to be commercialized in the following 24 months across a range of cancers including lung, breast, and ovarian.” In addition to the Pulmotype lung cancer test, AGI’s pipeline includes theranostic tests designed to assist in the selection of therapies, as well as a breast cancer panel that could be incorporated for use with Clarient’s Insight Dx Breast Cancer Profile.

Lab21 Acquires Selah Technologies

Lab21, a U.K.-based healthcare diagnostics company, announced the acquisition of Selah Technologies, a South Carolina-based company specializing in proprietary nanotechnologies for in vitro diagnostic products. Lab21 intends to develop new diagnostic products that have potential as rapid, low-cost, and sensitive tests based on Selah’s nanoparticle technology. Lab21 also announced the formation of Lab 21 Inc., a U.S.-based subsidiary to be headquartered in Greenville, S.C. As a new diagnostic service laboratory, Lab21 Inc. will conform to CLIA requirements and focus primarily on oncology testing. “The acquisition of Selah Technologies is a key step in the development of Lab21’s strategy as we look to expand our technology platforms as well as our global commercial operations,” said Graham Mullis, chief executive officer of Lab21. “The formation of Lab 21 Inc. is a significant investment and a major step forward in Lab21’s planned international expansion. The U.S. market is expected to be an exciting opportunity for Lab21 as we expand our market-leading products and services in the world’s largest diagnostic market.” Financial details regarding the acquisition of Selah Technologies and the establishment of Lab 21 Inc. were not disclosed.

Life Technologies Completes Acquisition of BioTrove

Life Technologies announced that it has completed its previously announced acquisition of BioTrove. BioTrove’s primary product is the OpenArray platform, a high-throughput gene expression and genotyping analysis system that can perform more than 3,000 PCR genotyping or qPCR gene expression assays simultaneously. Financial details of the acquisition were not disclosed.

Page Access: